

=> fil hcaplu
 FILE 'HCAPLUS' ENTERED AT 15:01:38 ON 01 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Jul 2003 VOL 139 ISS 1
 FILE LAST UPDATED: 30 Jun 2003 (20030630/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que
 L1 21631 SEA FILE=REGISTRY ABB=ON HEXANEDIOL/BI
 L2 10611 SEA FILE=REGISTRY ABB=ON PENTANEDIOL/BI
 L3 2059 SEA FILE=REGISTRY ABB=ON HEPTANEDIOL/BI
 L4 29042 SEA FILE=HCAPLUS ABB=ON L1 OR HEXANEDIOL?
 L5 20324 SEA FILE=HCAPLUS ABB=ON L2 OR PENTANEDIOL?
 L6 2693 SEA FILE=HCAPLUS ABB=ON L3 OR HEPTANEDIOL?
 L8 1 SEA FILE=HCAPLUS ABB=ON PURIFICATION+ALL/CV (L) (PEPTIDE? OR PROTEIN?) AND (L4 OR L5 OR L6)

=> d ibib abs hitrn l8

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:717837 HCAPLUS
 DOCUMENT NUMBER: 131:314241
 TITLE: Stabilized protein crystals, formulations containing them and methods of making them
 INVENTOR(S): Margolin, Alexey L.; Khalaf, Nazer K.; St. Clair, Nancy L.; Rakestraw, Scott L.; Shenoy, Bharni C.
 PATENT ASSIGNEE(S): Altus Biologics Inc., USA
 SOURCE: PCT Int. Appl., 201 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955310	A1	19991104	WO 1999-US9099	19990427
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				

TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2330476 AA 19991104 CA 1999-2330476 19990427
AU 9937646 A1 19991116 AU 1999-37646 19990427
AU 757991 B2 20030313
EP 1073421 A1 20010207 EP 1999-920064 19990427

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2002512949 T2 20020508 JP 2000-545510 19990427
US 2002045582 A1 20020418 US 1999-374132 19990810
US 6541606 B2 20030401

PRIORITY APPLN. INFO.:

US 1998-83148P P 19980427
US 1998-224475 A2 19981231
US 1997-70274P P 19971231
WO 1999-US9099 W 19990427

AB Methods are provided for the stabilization, storage, and delivery of biol. active macromols., such as proteins, peptides and nucleic acids. Methods are provided for the crystn. of proteins and nucleic acids and for the prepn. of stabilized protein or nucleic acid crystals for use in dry or slurry formulations in pharmaceutical and veterinary formulations, diagnostics, cosmetics, food, and agricultural feeds. The crystals are stabilized by addn. of excipients such as carbohydrates or by encapsulating them in a polymeric carrier. Methods are presented for encapsulating proteins, glycoproteins, enzymes, antibodies, hormones, and peptide crystals or crystal formulations into compns. for biol. delivery to humans and animals. Thus, lipase from *Candida rugosa* was dissolved in distd. water, treated with celite, adjusted to pH 4.8 with AcOH, filtered, ultrafiltered to remove proteins of <30 kDa mol. wt., and crystn. was initiated by addn. of 2-methyl-2,4-pentanediol. Sucrose was added to the mother liquor to a concn. of 10%, and the crystals were sepd. by centrifugation, suspended in EtOH, and air dried at room temp. Alternatively, the lipase crystals were crosslinked and encapsulated in lactic acid/glycolic acid copolymer; the microspheres formed were 90 .mu.m in diam.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d stat que

L1 21631 SEA FILE=REGISTRY ABB=ON HEXANEDIOL/BI
L2 10611 SEA FILE=REGISTRY ABB=ON PENTANEDIOL/BI
L3 2059 SEA FILE=REGISTRY ABB=ON HEPTANEDIOL/BI
L4 29042 SEA FILE=HCAPLUS ABB=ON L1 OR HEXANEDIOL?
L5 20324 SEA FILE=HCAPLUS ABB=ON L2 OR PENTANEDIOL?
L6 2693 SEA FILE=HCAPLUS ABB=ON L3 OR HEPTANEDIOL?
L9 712 SEA FILE=HCAPLUS ABB=ON (PURIF? OR SEPARAT? OR ISOLAT?) AND CHROMATO? AND (L4 OR L5 OR L6)
L10 97 SEA FILE=HCAPLUS ABB=ON L9(L)ELUT?
L11 20 SEA FILE=HCAPLUS ABB=ON L10 AND MOLECULE?
L12 3 SEA FILE=HCAPLUS ABB=ON L11 AND BUFFER?

=> d ibib abs hitrn l12 1-3

L12 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:736273 HCAPLUS

DOCUMENT NUMBER: 137:259637
 TITLE: Method for **purification** of **molecules**
 using unbranched terminal alkyldiols
 INVENTOR(S): Hauser, Terry Allen; Hayenga, Kirk James
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074791	A1	20020926	WO 2002-EP3021	20020314
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002183483	A1	20021205	US 2001-813093	20010319

PRIORITY APPLN. INFO.:

US 2001-813093 A 20010319

AB The current invention provides methods for **mol. purifn**
 . by RP-LC and RP-HPLC that uses unbranched terminal alkyldiols as
eluting solvents. In particular, the present invention
purifies mols., particularly proteins and peptides, on reverse
 phase liq. **chromatog.** columns using a **buffer** contg.
 either 1,5-**pentanediol**, 1,6-**hexanediol** or 1,7-
heptanediol. Growth hormone antagonist and five other peptides
 with **purified** on an Amberchrom CG71-M column **eluted**
 with a linear gradient of 1,6-**hexanediol** in Tris HCl, pH 7.5.

IT 111-29-5, 1,5-Pentanediol 629-11-8, 1,6-
 Hexanediol 629-30-1, 1,7-Heptanediol

RL: NUU (Other use, unclassified); USES (Uses)
 (method for **purifn.** of mols. using unbranched terminal
 alkyldiols as **eluting** solvents)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:537520 HCAPLUS

DOCUMENT NUMBER: 135:134285

TITLE: **Purification** of polypeptides by
 reversed-phase liquid **chromatography**

INVENTOR(S): Fahrner, Robert Lee; Reifsnnyder, David

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: U.S., 27 pp.
 CODEN: USXXAM

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6265542	B1	20010724	US 1998-168548	19981008

no did.

Searched by M. Smith

102e

PRIORITY APPLN. INFO.: US 1997-63119P P 19971024

AB A process for **purifying** polypeptide mols. from contaminants is provided. In this process a mixt. contg. the **mol.** (peptide, polypeptide, or biol. active non-peptidyl compd.) and its contaminants is loaded onto a reversed-phase liq. **chromatog.** column and the **mol.** is **eluted** from the column with a **buffer** contg. hexylene glycol. Lysozyme was **sepd.** from ovalbumin, substance P was **sepd.** from bradykinin, and hydrocortisone was **sepd.** from progesterone by reversed-phase liq. **chromatog.** using hexylene glycol.

IT 126-30-7, Neopentyl glycol
RL: PRP (Properties)
(as solvent in IGF-I **purifn.** from mutant; **purifn.** of polypeptides by reversed-phase liq. **chromatog.**)

IT 107-41-5, Hexylene glycol
RL: NUU (Other use, unclassified); USES (Uses)
(**purifn.** of polypeptides by reversed-phase liq. **chromatog.**)

REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:297447 HCAPLUS

DOCUMENT NUMBER: 130:293612

TITLE: **Purification** of proteins and other **molecules** using reversed-phase liq. **chromatog.** and **elution** using hexylene glycol.

INVENTOR(S): Fahrner, Robert L.; Reifsnnyder, David

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921889	A1	19990506	WO 1998-US21238	19981008
W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
CA 2306447	AA	19990506	CA 1998-2306447	19981008
AU 9910725	A1	19990517	AU 1999-10725	19981008
AU 740665	B2	20011108		
EP 1025126	A1	20000809	EP 1998-953320	19981008
EP 1025126	B1	20030416		
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
JP 2001521044	T2	20011106	JP 2000-517996	19981008
AT 237636	E	20030515	AT 1998-953320	19981008
ZA 9809424	A	20000417	ZA 1998-9424	19981015
PRIORITY APPLN. INFO.:			US 1997-957760 A	19971024

WO 1998-US21238 W 19981008

AB This invention provides a process for **purifying** a **mol.** selected from the group consisting of peptides, proteins and biol. active non-peptidyl compds. The method consists of loading a mixt. contg. the **mol.** onto a reversed-phase liq. **chromatog.** column and **eluting** the **mol.** from the column with a **buffer** contg. the non-flammable eluent hexylene glycol. The process is illustrated using insulin-like growth factor I.

IT 107-41-5, Hexylene glycol
 RL: BUU (Biological use, unclassified); NUU (Other use, unclassified); BIOL (Biological study); USES (Uses)
 (purifn. of proteins and other mols. using reversed-phase liq. **chromatog.** and **elution** using hexylene glycol.)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d stat que

L1 21631 SEA FILE=REGISTRY ABB=ON HEXANEDIOL/BI
 L2 10611 SEA FILE=REGISTRY ABB=ON PENTANEDIOL/BI
 L3 2059 SEA FILE=REGISTRY ABB=ON HEPTANEDIOL/BI
 L4 29042 SEA FILE=HCAPLUS ABB=ON L1 OR HEXANEDIOL?
 L5 20324 SEA FILE=HCAPLUS ABB=ON L2 OR PENTANEDIOL?
 L6 2693 SEA FILE=HCAPLUS ABB=ON L3 OR HEPTANEDIOL?
 L8 1 SEA FILE=HCAPLUS ABB=ON PURIFICATION+ALL/CV (L) (PEPTIDE? OR PROTEIN?) AND (L4 OR L5 OR L6)
 L9 712 SEA FILE=HCAPLUS ABB=ON (PURIF? OR SEPARAT? OR ISOLAT?) AND CHROMATO? AND (L4 OR L5 OR L6)
 L10 97 SEA FILE=HCAPLUS ABB=ON L9(L)ELUT?
 L11 20 SEA FILE=HCAPLUS ABB=ON L10 AND MOLECULE?
 L12 3 SEA FILE=HCAPLUS ABB=ON L11 AND BUFFER?
 L13 2 SEA FILE=HCAPLUS ABB=ON (PURIF? OR SEPARAT? OR ISOLAT?) AND CHROMAT? AND ALKYLDIOL?(L) (ELUT? OR BUFFER?)
 L14 1 SEA FILE=HCAPLUS ABB=ON L13 NOT (L12 OR L8)

=> d ibib abs hitrn 114

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:640094 HCAPLUS

DOCUMENT NUMBER: 131:331689

TITLE: Determination of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyldaunorubicin and its 13-hydroxy metabolite by direct injection of human plasma into a column-switching liquid **chromatography** system with mass spectrometric detection

AUTHOR(S): Breda, M.; Basileo, G.; Fonte, G.; Long, J.; James, C. A.

CORPORATE SOURCE: Drug Metabolism Research, Pharmacia and Upjohn, Milan, 20014, Italy

SOURCE: Journal of Chromatography, A (1999), 854(1 + 2), 81-92
 CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A selective, sensitive, and fully automated column-switching HPLC system using direct injection of human blood plasma followed by MS detection was developed to det. the concns. of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyldaunorubicin (PNU-159548) and its 13-hydroxy metabolite

(PNU-169884). A 50-.mu.L human plasma sample was directly introduced into a C4-alkyldiol silica clean-up column **sepg.** analytes from proteins and polar endogenous compds. using water and methanol as the mobile phase. The fraction contg. PNU-159548 and its metabolite was back-flushed and transferred onto the anal. column. The compds. were **sepd.** on a Zorbax SB C8 column (150.times.4.6 mm, 5 .mu.m) under gradient **elution** conditions with the mobile phase of acetonitrile and 2 mM ammonium formate pH 3.5. The MS detection was by atm. pressure ionization with multiple reaction monitoring in pos. ion mode. Linearity was demonstrated over the calibration range of 0.051-10.291 ng/mL for PNU-159548 and 0.104-10.434 ng/mL for PNU-169884. The assay was validated with respect to accuracy, precision, and analyte stability. The method is suitable for use in Phase I clin. studies.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT